摘要Objective:Danhong injection(DHI)is commonly used in China to treat chronic stable angina(CSA),demonstrating significant clinical efficacy and safety.The present study aimed to estimate the cost-effectiveness of DHI combined with standard treatment(ST)com-pared with ST alone in patients with CSA.Methods:A Markov model with a 3-month cycle and a 1-year time horizon was used to assess the cost-effectiveness of DHI+ST for CSA.Health outcomes were measured as quality-adjusted life years(QALYs),and societal perspective costs were collected in China.Cost-effectiveness was evaluated using the incremental cost-effectiveness ratio(ICER).Sensitivity analysis was performed to test the robustness of results to parameter uncertainty.Results:Analysis demonstrated DHI+ST provided 0.8190 QALYs at an average cost of $3644.24,while ST yielded 0.7884 QALYs costing $2739.54 over 1 year.The incremental analysis indicated DHI+ST dominance,with an ICER of $29,588.91 per QALY gained compared with ST.One-way sensitivity analysis confirmed the robustness of base case findings,and probabilistic sensitivity analysis suggested a 61.66％probability of DHI+ST being cost-effective over ST at a $37,663.26 per QALY threshold.Conclusion:From a societal perspective in China,DHI+ST appears cost-effective for the treatment of CSA compared with ST alone.These findings support recommending DHI as a clinically valuable and cost-effective option in CSA treatment guidelines.